AP-1 signaling modulates cardiac fibroblast stress responses

被引:3
|
作者
Whitehead, Alexander J. [1 ,2 ]
Atcha, Hamza [1 ,2 ]
Hocker, James D. [4 ]
Ren, Bing [4 ,5 ]
Engler, Adam J. [1 ,2 ,3 ]
机构
[1] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA
[2] Sanford Consortium Regenerat Med, La Jolla, CA 92037 USA
[3] Univ Calif San Diego, Biomed Sci Program, La Jolla, CA 92093 USA
[4] Ludwig Inst Canc Res, Lab Gene Regulat, La Jolla, CA 92037 USA
[5] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA
基金
美国国家卫生研究院; 美国国家科学基金会;
关键词
Inflammation; Fibrosis; Myocardial regeneration; Gene expression; Gene regulation; Myocardial infarction; TRANSCRIPTION FACTORS; GENE-EXPRESSION; HEART; DISEASE; MATRIX; GATA5; PROLIFERATION; MACROPHAGES; ACTIVATION; ALIGNMENT;
D O I
10.1242/jcs.261152
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Matrix remodeling outcomes largely dictate patient survival post myocardial infarction. Moreover, human-restricted noncoding regulatory elements have been shown to worsen fibrosis, but their mechanism of action remains elusive. Here, we demonstrate, using induced pluripotent stem cell-derived cardiac fibroblasts (iCFs), that inflammatory ligands abundant in the remodeling heart after infarction activate AP-1 transcription factor signaling pathways resulting in fibrotic responses. This observed signaling induces deposition of fibronectin matrix and is further capable of supporting immune cell adhesion; pathway inhibition blocks iCF matrix production and cell adhesion. Polymorphisms in the noncoding regulatory elements within the 9p21 locus (also referred to as ANRIL) redirect stress programs, and in iCFs, they transcriptionally silence the AP-1 inducible transcription factor GATA5. The presence of these polymorphisms modulate iCF matrix production and assembly and reduce cell-cell signaling. These data suggest that this signaling axis is a critical modulator of cardiac disease models and might be influenced by noncoding regulatory elements.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Activator protein-1 (AP-1) signaling inhibits the growth of Ewing sarcoma cells in response to DNA replication stress
    Gordon, David
    Croushore, Emma
    Koppenhafer, Stacia
    Goss, Kelli
    Geary, Elizabeth
    CANCER RESEARCH, 2023, 83 (07)
  • [22] Lutein attenuates angiotensin II- induced cardiac remodeling by inhibiting AP-1/IL-11 signaling
    Chen, Youming
    Wang, Lan
    Huang, Shixing
    Ke, Jiangfeng
    Wang, Qing
    Zhou, Zhiwen
    Chang, Wei
    REDOX BIOLOGY, 2021, 44
  • [23] Puerarin Suppresses Angiotensin II-Induced Cardiac Hypertrophy by Inhibiting NADPH Oxidase Activation and Oxidative Stress-Triggered AP-1 Signaling Pathways
    Chen, Gang
    Cao, Qiang
    Cui, Xiangli
    Pan, Shifen
    Shen, Chong
    Liu, Lihong
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2015, 18 (02): : 235 - 248
  • [24] Calorie restriction modulates redox-sensitive AP-1 during the aging process
    Kim H.J.
    Jung K.J.
    Seo A.Y.
    Choi J.S.
    Yu B.P.
    Chung H.Y.
    Journal of the American Aging Association, 2002, 25 (3) : 123 - 130
  • [25] Calorie restriction modulates redox-sensitive AP-1 during the aging process
    Kim, HJ
    Jung, KJ
    Seo, AY
    Choi, JS
    Yu, BP
    Chung, HY
    JOURNAL OF THE AMERICAN AGING ASSOCIATION, 2002, 25 (03) : 123 - 130
  • [26] Dextromethorphan modulates the AP-1 DNA-binding activity induced by kainic acid
    Kim, HC
    Bing, GY
    Jhoo, WK
    Ko, KH
    Kim, WK
    Lee, DC
    Shin, EJ
    Hong, JS
    BRAIN RESEARCH, 1999, 824 (01) : 125 - 132
  • [27] Enteral arginine modulates the effect of pharmacologic inhibition of AP-1 on iNOS in the postischemic gut
    Ban, K.
    Gonzalez, E. A.
    Kone, B. C.
    Kozar, R. A.
    SHOCK, 2007, 27 : 78 - 78
  • [28] Homocysteine decreases endothelin-1 expression by interfering with the AP-1 signaling pathway
    Drunat, S
    Moatti, N
    Demuth, K
    FREE RADICAL BIOLOGY AND MEDICINE, 2002, 33 (05) : 659 - 668
  • [29] AP-1 and colorectal cancer
    Ashida R.
    Tominaga K.
    Sasaki E.
    Watanabe T.
    Fujiwara Y.
    Oshitani N.
    Higuchi K.
    Mitsuyama S.
    Iwao H.
    Arakawa T.
    InflammoPharmacology, 2005, 13 (1-3) : 113 - 125
  • [30] AP-1 - Introductory remarks
    Wagner, EF
    ONCOGENE, 2001, 20 (19) : 2334 - 2335